- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02378220
Pharmacogenetic Testing Among Home Health Patients
September 18, 2019 updated by: Genelex Corporation
A Pilot Prospective, Randomized Controlled Trial Assessing the Clinical Impact of Integrated Pharmacogenetic Testing on Selected OASIS Metrics, Re-hospitalizations and Emergency Department Visits
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
In this open-label trial, a pharmacist will make medication therapy recommendations using YouScript® Personalized Prescribing System for patients who receive genetic testing and standard drug information resources per usual for patients who do not undergo pharmacogenetic testing.
Study Overview
Status
Completed
Conditions
- Drug Interaction Potentiation
- Adverse Drug Events
- Adverse Drug Reactions
- Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant
- Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant
- Drug Metabolism, Poor, CYP2D6-RELATED
- Drug Metabolism, Poor, CYP2C19-RELATED
- Cytochrome P450 Enzyme Deficiency
- Cytochrome P450 CYP2D6 Enzyme Deficiency
- Cytochrome P450 CYP2C9 Enzyme Deficiency
- Cytochrome P450 CYP2C19 Enzyme Deficiency
- Cytochrome P450 CYP3A Enzyme Deficiency
- Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Intervention / Treatment
Detailed Description
Both groups will be followed for 60 days.
The number of re-hospitalizations and emergency department (ED) visits will be recorded as well as time to first re-hospitalization and time to first ED visit.
Select Outcome and Assessment Information Set (OASIS) metrics (e.g.
M1034, M1242, M1710, M1720, M1745, M2110) and Patient Health Questionnaire (PHQ)-2 will be evaluated and documented at time of admission to home health, at 30 days, and at 60 days for improvement in overall status, pain, confusion, anxiety, depression, disruptive behavior, and the need for assistance with activities of daily living (ADLs) and instrumental activities of daily living (IADLs).
The number of falls will be collected as well as the proportion of YouScript® recommendations accepted by study pharmacist and passed on to clinicians and the proportion of recommendations accepted by clinicians.
Study Type
Interventional
Enrollment (Actual)
110
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Searcy, Arkansas, United States, 72143
- White County Medical Center Home Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 50 or older.
- Willing and able to provide informed consent for study participation either directly or by a legally authorized representative (LAR).
- Presently taking or beginning treatment with at least one of the following oral forms of medication (excluding medications taken PRN) (generic name given with major U.S. brand name given in parentheses). These medications are subject to significant drug-gene interactions as defined by FDA boxed warning, FDA cautionary labeling, clinical literature or a YouScript® algorithm-predicted significant effect: Amitriptyline (Elavil), Aripiprazole (Abilify), Atomoxetine (Strattera), Carvedilol (Coreg), Celecoxib (Celebrex), Citalopram (Celexa), Clobazam (Onfi), Clomipramine (Anafranil), Clopidogrel (Plavix), Clozapine (Clozaril), Codeine [Tylenol #3 (combo)], Desipramine (Norpramin), Dextromethorphan (Delsym), Diazepam (Valium), Doxepin (Sinequan), Escitalopram (Lexapro), Esomeprazole (Nexium), Fesoterodine (Toviaz), Flecainide (Tambocor), Fluoxetine (Prozac), Flurbiprofen (Ansaid), Fluvoxamine (Luvox), Haloperidol (Haldol), Hydrocodone , Ibuprofen (Motrin), Iloperidone (Fanapt), Imipramine (Tofranil), Indomethacin (Indocin), Meloxicam (Mobic), Metoprolol (Toprol XL), Mexiletine (Mexitil), Nortriptyline (Pamelor), Omeprazole (Prilosec), Oxycodone (Oxycontin), Paroxetine (Paxil), Perphenazine (Trilafon), Phenobarbital (Luminal), Phenytoin (Dilantin), Pimozide (Orap), Piroxicam (Feldene), Proguanil [(Malarone (combo)], Propafenone (Rythmol), Propranolol (Inderal), Risperidone (Risperdal), Sertraline (Zoloft), Tetrabenazine (Xenazine), Thioridazine (Mellaril), Timolol (Apotimol), Tolterodine (Detrol), Torsemide (Demadex), Tramadol (Ultram), Trimipramine (Surmontil), Venlafaxine (Effexor), Voriconazole (Vfend), Vortioxetine (Brintellix), Warfarin (Coumadin).
Exclusion Criteria:
- Previous CYP testing (CPT codes 81225, 81226, 81227, 81355, 81401)
- History of organ transplant (199.2; 238.77; 414.06; 414.07; 996.80-996.89; E878.0; V42.0-V42.7; V42.81-V42.84; V42.89; V42.9; V45.87; V49.83; V58.44)
- Current malabsorption syndrome (579.0), including the following: Intestinal malabsorption (579.8, 579.9), Postoperative malabsorption (579.3), or Short bowel syndrome (579.3)
- Treatment of invasive solid tumors or hematologic malignancies in the last year, excluding in situ cancers or non-melanoma skin cancer (basal cell carcinoma)
- End Stage Renal Disease (ESRD)
- Persistent acute renal failure: complete loss of kidney function >4 weeks (requiring dialysis)
- Renal failure by: Glomerular filtration rater (GFR): SCr > 3 times baseline or GFR decreased 75% or SCr ≥4 mg/dL; acute rise ≥0.5 mg/dL; OR Urine Output (UO): UO < 0.3 mL/kg/h 24 h (oliguria) or anuria 12 h.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Controls ("not tested")
Treatment as usual (e.g.
review of potential drug-drug interactions via Lexicomp Online)
|
|
Active Comparator: Intervention ("tested")
Patients in the "tested" group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System.
The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers.
|
Pharmacogenetic testing via YouScript® Personalized Prescribing System
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Re-hospitalizations at 30 and 60 Days
Time Frame: 30 days, 60 days post discharge
|
The primary outcomes included the number of re-hospitalizations at 30 and 60 days.
|
30 days, 60 days post discharge
|
The Primary Outcomes Included the Number of Emergency Department Visits at 30 and 60 Days.
Time Frame: 30 days, 60 days post discharge
|
Assessed the number of Emergency Department visits at 30 and 60 days post discharge with pharmacogenetic testing and YouScript® Personalized Prescribing system.
|
30 days, 60 days post discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to 1st Re-hospitalization
Time Frame: 30 days, 60 days
|
To assess time to first re-hospitalization, we compared the exploratory time-to-event outcomes between the tested and untested groups at 30 days and 60 days.
These outcomes were measured using cumulative percentage events at 30 and 60 days, referring to the percentage of subjects re-hospitalized before or at 30 and 60 days.
|
30 days, 60 days
|
Time to 1st Emergency Department Visit
Time Frame: 30 days, 60 days
|
To assess time to first emergency department visit, we compared the exploratory time-to-event outcomes (time to 1st ED visit) between the tested and untested groups at 30 days and 60 days.
These outcomes were measured using cumulative percentage events at 30 and 60 days, referring to the percentage of subjects who visited the emergency department before or at 30 and 60 days.
|
30 days, 60 days
|
Overall Status as Measured by Outcome and Assessment Information Set (OASIS) Scale
Time Frame: 30 days, 60 days post discharge
|
We assessed the impact of genetic testing on overall status according to OASIS M1034 at 30 and 60 days post discharge.
OASIS measures various data items to assess home health care quality and performance.
OASIS M1034, one data point in the OASIS system, measures overall patient status on a scale of 0 to 3, with a lower score indicating better overall status.
|
30 days, 60 days post discharge
|
Pain as Measured by OASIS Scale
Time Frame: 30 days, 60 days post discharge
|
We assessed the impact of genetic testing on patient pain frequency according to OASIS M1242 at 30 and 60 days post discharge.
OASIS measures various data items to assess home health care quality and performance.
OASIS M1242, one data point in the OASIS system, measures patient pain frequency on a scale of 0 to 4, with a lower score indicating less frequent pain.
|
30 days, 60 days post discharge
|
Confusion as Measured by OASIS Scale
Time Frame: 30 days, 60 days post discharge
|
We assessed the impact of genetic testing on frequency of confusion according to OASIS M1710 at 30 and 60 days post discharge.
OASIS measures various data items to assess home health care quality and performance.
OASIS M1710, one data point in the OASIS system, measures patient confusion frequency on a scale of 0 to 4, with a lower score indicating less frequent confusion.
|
30 days, 60 days post discharge
|
Anxiety as Measured by OASIS Scale
Time Frame: 30 days, 60 days post discharge
|
We assessed the impact of genetic testing on frequency of anxiety according to OASIS M1720 at 30 and 60 days post discharge.
OASIS measures various data items to assess home health care quality and performance.
OASIS M1720, one data point in the OASIS system, measures patient confusion frequency on a scale of 0 to 3, with a lower score indicating less frequent confusion.
|
30 days, 60 days post discharge
|
Depression as Measured by Patient Health Questionnaire (PHQ)-2 Scale
Time Frame: 30 days, 60 days post discharge
|
We assessed the impact of genetic testing on frequency of depressive mood according to PHQ-2 at 30 and 60 days post discharge.
PHQ-2 evaluates patient depression by assessing two factors: frequency of little interest or pleasure in doing things and frequency of feeling down, depressed, or hopeless.
This outcome measure assessed the second factor, frequency of feeling down or depressed.
The scale for this factor ranges from 0 to 3, with a lower score represented less frequent depressive feelings.
|
30 days, 60 days post discharge
|
Disruptive Behavior as Measured by OASIS Scale
Time Frame: 30 days, 60 days post discharge
|
We assessed the impact of genetic testing on frequency of disruptive behavior according to OASIS M1745 at 30 and 60 days post discharge.
OASIS measures various data items to assess home health care quality and performance.
OASIS M1745, one data point in the OASIS system, measures frequency of disruptive behavior by patient on a scale of 0 to 5, with a lower score indicating less frequent disruptive behavior.
|
30 days, 60 days post discharge
|
Activities of Daily Living as Measured by OASIS Scale
Time Frame: 30 days, 60 days post discharge
|
We assessed the impact of genetic testing on the frequency of activities of daily living (ADL) and instrumental activities of daily living (IADL) assistance according to OASIS M2110 at 30 and 60 days post discharge.
OASIS measures various data items to assess home health care quality and performance.
OASIS M2110, one data point in the OASIS system, measures frequency of receiving ADL/IADL assistance on a scale of 0 to 5, with a lower score indicating less frequent assistance.
|
30 days, 60 days post discharge
|
Number of Falls as Measured by Tabulation
Time Frame: 60 days
|
To assess whether YouScript® testing decreases falls
|
60 days
|
Number of Pharmacist-accepted of Recommendations as Measured by Tabulation
Time Frame: 60 days
|
To assess the proportion of YouScript® Personalized Prescribing System recommendations accepted by the study pharmacist and passed on to clinicians.
|
60 days
|
Number of Clinician-accepted of Recommendations as Measured by Tabulation
Time Frame: 60 days
|
To assess the proportion of study pharmacist recommendations acted on by clinicians.
|
60 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lindsay Elliott, PharmD, Harding University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
- Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial
- PGx Testing Firm Genelex Publishes RCT, Spins Out Analytics Unit in Effort to Improve Adoption
- Genomics, Clinical Decision Support Combo Cuts ED Visits by 42%
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
February 24, 2015
First Submitted That Met QC Criteria
February 27, 2015
First Posted (Estimate)
March 4, 2015
Study Record Updates
Last Update Posted (Actual)
September 20, 2019
Last Update Submitted That Met QC Criteria
September 18, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Interaction Potentiation
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
Il-Yang Pharm. Co., Ltd.CompletedDrug Interaction PotentiationKorea, Republic of
-
National Taiwan University HospitalCompletedDrug Interaction PotentiationTaiwan
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
SK Chemicals Co., Ltd.CompletedDrug Interaction Potentiation
-
Tianjin Medical University General HospitalCompleted
-
Il-Yang Pharm. Co., Ltd.CompletedDrug Interaction PotentiationKorea, Republic of
-
F-star Therapeutics, Inc.PRA Health SciencesCompletedDrug Interaction PotentiationNetherlands
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
LEO PharmaCompletedDrug Interaction PotentiationGermany
Clinical Trials on Pharmacogenetic testing
-
University of CalgaryRecruiting
-
Avera McKennan Hospital & University Health CenterCompletedDepressionUnited States
-
Maastricht University Medical CenterKing's College London; State University of New York - Upstate Medical University and other collaboratorsRecruitingPsychotic Disorders | Mood Disorders | Anxiety DisordersUnited States, Germany, Netherlands, Spain, Serbia, Romania, United Kingdom
-
Duke UniversityNational Institute of General Medical Sciences (NIGMS)Completed
-
University of ArizonaUnknownDepression | Obsessive-Compulsive Disorder | Generalized Anxiety Disorder
-
Avera McKennan Hospital & University Health CenterCompletedEvaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes (PGx-TIME)Major Depressive Disorder 1United States
-
Anna VlasovaRussian Medical Academy of Continuous Professional Education; Morozov Children...CompletedDrug TherapyRussian Federation
-
Medstar Health Research InstituteKailos Genetics, Inc.Active, not recruitingChronic PainUnited States
-
Avera McKennan Hospital & University Health CenterCompletedMajor Depressive DisorderUnited States
-
Cairo UniversityAin Shams University; Misr International UniversityUnknown